Loading
A phase 2 trial of Cemiplimab, Fianlimab in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients is a phase 2 interventional study registered as NCT03916627 by Regeneron Pharmaceuticals, with 65 participants enrolled, started 2019-07-23 and due to reach its primary completion in 2025-03-31. Interventions recorded: cemiplimab, Platinum Doublet, fianlimab. Conditions listed: Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/